Howard Kallender

Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

Manish A. Shah, Zev A. Wainberg, Daniel V.T. Catenacci et al. · PLoS ONE · 2013 · 206 citations · Full text

Medicine, Oncology, Pharmacology +17

Purification and Biochemical Characterization of theMycobacterium tuberculosis β-Ketoacyl-acyl Carrier Protein Synthases KasA and KasB

Merrill L. Schaeffer, Gautam Agnihotri, Craig Volker et al. · Journal of Biological Chemistry · 2001 · 141 citations · Full text

Life Sciences, Biochemistry, Microbiology +15

Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies

Kim Papp, Jacek C. Szepietowski, Leon Kircik et al. · Journal of the American Academy of Dermatology · 2022 · 92 citations · Full text

Medicine, Dermatology, Pharmacotherapy +11

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Tanguy Y. Seiwert, John Sarantopoulos, Howard Kallender et al. · Investigational New Drugs · 2012 · 88 citations · Full text

Medicine, Oncology, Pharmacology +16

A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

Thomas Yau, Riccardo Lencioni, Wattana Sukeepaisarnjaroen et al. · Clinical Cancer Research · 2016 · 77 citations · Full text

Pharmacy, Oncology, Pharmacology +17